Breaking Finance News

Zacks Investment Research downgraded R1 RCM Inc (NYSE:RCM) to Hold in a report released today.

Boasting a price of $3.69, R1 RCM Inc (NYSE:RCM) traded -1.60% lower on the day. With the last stock price close down -20.42% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. R1 RCM Inc has recorded a 50-day average of $4.56 and a two hundred day average of $3.87. Volume of trade was down over the average, with 297,541 shares of RCM changing hands under the typical 673,236

Zacks Investment Research has downgraded R1 RCM Inc (NYSE:RCM) to Hold in a statement released on 7/07/2017.

On 07/06/2017, Zacks Investment Research released a statement for R1 RCM Inc (NYSE:RCM) bumped up the target price from $0.00 to $4.00 that suggested an upside of 0.06%.

Performance Chart


With a total market value of $0, R1 RCM Inc has with a one year low of $2.64 and a one year high of $22.46 .

Brief Synopsis About R1 RCM Inc (NYSE:RCM)

R1 RCM Inc., formerly Accretive Health, Inc., is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers. Its primary service offering consists of end-to-end RCM, which the Company deploys through a co-managed relationship or an operating partner relationship. The Company's PAS offering assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes. The Company also provides customers with retrospective appeal management service support for both governmental and commercial payers. Its physicians conduct detailed retrospective reviews of medical records to identify medical necessity for hospital services and the required documentation to support an appeal.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.